Compare Crispr Therapeutics AG (CRSP) vs Hewlett Packard Enterprise Co (HPE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Hewlett Packard Enterprise Co — how do they compare? Crispr Therapeutics AG trades at $50.52 (market cap $4.97B), while Hewlett Packard Enterprise Co trades at $46.16 (market cap $65.63B). The key difference: Hewlett Packard Enterprise Co is far larger — about 13.2× Crispr Therapeutics AG's market cap, and Hewlett Packard Enterprise Co pays a 1.15% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | HPE | |
|---|---|---|
Market Cap | $4.97B | $65.63B |
Sector | Health | Technology |
52-Week High | $76.78 | $56.14 |
52-Week Low | $44.34 | $19.81 |
Enterprise Value | $3.32B | $81.58B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
HPE trades at $47.24, down 2.61% on the day, with a bullish technical signal from moving averages. Recent earnings beats and a consensus price target of $69.69 suggest upside potential. The company reported revenue of $34.30B in 2025, though net income fell sharply to $57M. Strong AI infrastructure demand and a nearly $6B backlog, as noted by The Motley Fool on July 9, 2026, highlight growth catalysts.
Outlook is positive with AI-driven demand boosting revenue projections to $38.8B in 2026. Risks include high debt-to-asset ratio of 29.48% in 2025 and margin pressures. Analysts are mixed with 46% buy ratings, indicating cautious optimism for long-term investors amid near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Hewlett Packard Enterprise Co
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →
